Sign in
TerminatedNo phase

Hybrid Therapy and Heart Team for Atrial Fibrillation

Key facts

Who runs it
University Hospital, Toulouse
Where
France3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
7 people enrolled
Started
8 Jul 2019
Ended
29 Jan 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Hybrid ablation
  • Percutaneous catheter ablation
Record updated
1 June 2026
Why it stopped
Difficulty finding patients

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (32)Hide the full registry criteria

Who can take part

  • To have a history of symptomatic persistent atrial fibrillation (AF) (continuous AF lasting 7 days or more) or long-standing persistent AF (continuous AF lasting for more than 12 months)
  • To be refractory to or intolerant to at least one class I (flecainide / propafenone) or III (sotalol / amiodarone) antiarrhythmic drug,
  • To be at least 18 years of age,
  • To agree to participate (signature of the informed consent)

Who cannot take part

  • A previous AF ablation procedure,
  • Indication for a permanent dual antiplatelet therapy
  • AF consecutive to electrolyte imbalance, thyroid disease, or other reversible non-cardiovascular cause,
  • Cardiac surgery (other than AF treatment) planned within 12 months,
  • Active infection or sepsis
  • Proven and untreated sleep apnoea syndrome,
  • History of blood clotting abnormalities
  • History of thoracic radiation,
  • History of myocarditis or pericarditisHistory of cardiac tamponade,
  • History of thoracotomy or cardiac surgery,
  • Patient with chronic obstructive pulmonary disease (COPD)
  • Left ventricular ejection fraction < 35%,
  • A longstanding persistent AF > 3 years,
  • A paroxysmal AF
  • Presence of left atrial appendage (LAA) thrombus,
  • Left atrial size ≥ 70ml/m² on transthoracic echocardiogram (TTE),
  • Contra-indication to heparin and/or oral anticoagulation
  • Contra-indication to transoesophageal echocardiogram (TEE)
  • Carotid stenosis > 80%,
  • Pleural adhesions,
  • Elevated hemi diaphragm
  • Occurrence of a cerebrovascular accident (CVA) or a transient ischemic attack (TIA) during the past 6 months,
  • Body-mass-index > 40 kg/m2,
  • Significant lung dysfunction
  • Contra-indication to anesthesia
  • Pregnancy,
  • Life expectancy less than 12 months,
  • Adults protected by the law

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Atrial fibrillation (AF) is the most common cardiac arrhythmia with a prevalence ranging from 5% over 60 years old to 17% after 85 years old. Besides hemodynamical compromises and occurrence of heart failure, stroke remains the most feared complication related to AF with a risk increased by 5-fold.

Read full original descriptionShow less

Catheter ablation with the aim of pulmonary veins isolation (PVI) has evolved as a standardized treatment option in paroxysmal AF (PAF), supported by the current guidelines. However, due to advanced electrical and structural remodeling, catheter ablation for persistent AF is rather disappointing with a limited success rate, at least after a single procedure. Due to these shortcomings, minimally invasive thoracoscopic surgical techniques have gained attention with good results in persistent AF patients. Comparison between thoracoscopic surgical ablation and catheter ablation have shown that surgical ablation was associated with higher success rates, less redo procedures but also with higher complication rates. The main issue with surgical ablation is the difficulty to check the ablation lines and pulmonary vein isolation, which are the cornerstones for achieving good long-term results.

Hybrid therapy, combining both epicardial surgical and endocardial catheter ablation is expected to be the most effective technique. It would avoid incomplete lesions or incomplete pulmonary vein isolation, and would provide complete lesion set. Hybrid therapy of AF has been compared with mini-invasive surgical ablation of AF, showing a significant higher rate of sinus rhythm achievement in the hybrid therapy group. However, no comparative clinical trials data are currently available in the setting of persistent AF comparing hybrid ablation and conventional catheter ablation.

The 2 groups in the trial

  • Hybrid ablation procedureTreatment being tested

    In the hybrid ablation procedure, the epicardial surgical ablation procedure will be combined with percutaneous endocardial catheter ablation procedure in a single step procedure.

    Treatment: Hybrid ablation

  • Percutaneous endocardial catheter ablation procedureExisting treatment, for comparison

    In the percutaneous catheter ablation arm, the procedure will be performed according to the current guidelines (pulmonary vein isolation, linear ablation and fragmented potentials ablation if needed, with the achievement of sinus rhythm during the procedure being the optimal endpoint).

    Treatment: Percutaneous catheter ablation

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison of the Efficacy of Hybrid Ablative Therapy for Patients With Persistent Atrial Fibrillation Versus Conventional Catheter Ablation
Record updated
1 June 2026